Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.
Rush University Medical Center
Conditions and Treatments
Search by Topic or Doctor's Name
Doctors at Rush Focus on You
At the end of the visit, my goal is to have the patients feel more informed and to feel like their issues have been properly addressed.
— Octavio Vega, MD, internist
I enjoy the challenges of piecing together the puzzle – putting difficult, complicated signs and symptoms together and trying to formulate a diagnosis.
— Patricia Graham, MD, internist
Hear more from doctors at Rush.
Directions and Parking
Health & Wellness
Health News and Advice to Fit Your Life
The choices you make each day can have a huge effect on your health. Rush offers a wealth of resources to help you make good ones.
5 Things You Can Do to Prevent CancerHow you can devise a cancer prevention action plan.
Combating Social Media DysmorphiaHow to love yourself — and your selfies — without filters or fillers.
About RushThe Rush SystemPatient StoriesNational Recognition and AccreditationsRush News
Quality and Safety at RushPatient Satisfaction and FeedbackRush in the CommunityDiversity and Inclusion
Disability Rights and AccommodationsCommitment to LGBTQ Health CareVolunteeringBondholder Information
Risk-stratified randomized phase III testing of blinatumomab (IND# I17467, NSC# 765986) in first relapse of childhood B-lymphoblastic leukemia (B-ALL).
Treatment of children with all stages of hepatoblastoma with temsirolimus (IND#122782, NSC#683864) added to high risk stratum treatment.
A randomized phase 3 study of brentuximab vedotin (SGN-35, IND #117117) for newly diagnosed high-risk classical Hodgkin lymphoma (cHL) in children and young adults.
A phase III randomized trial for patients with de novo AML using bortezomib and sorafenib (IND# I14480, NSC# 681239, NSC# 724772) for patients with high allelic ratio FLT3/ITD.
A randomized phase 2 trial of brentuximab vedotin (SGN35, NSC# 749710), or crizotinib (NSC#749005, commercially labeled) in combination with chemotherapy for newly diagnosed patients with anaplastic large cell lymphoma (ALCL) IND#117117.
A phase II study for the treatment of non-metastatic desmoplastic medulloblastoma in children less than 4 years of age.